牛牛AI助理已提取核心訊息
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
與CRISPR Therapeutics AG [CRSP] 有關聯的喬治·西蒙於2024年2月27日對該公司的普通股進行了重大收購。該交易目前正在進行中，涉及以每股71.50美元的統一價格購買總共1,048,951股股票。這些交易之後，西蒙在CRISPR Therapeutics中持有的股份爲769,196股。間接受益所有權的性質詳見與交易記錄相關的附註。
與CRISPR Therapeutics AG [CRSP] 有關聯的喬治·西蒙於2024年2月27日對該公司的普通股進行了重大收購。該交易目前正在進行中，涉及以每股71.50美元的統一價格購買總共1,048,951股股票。這些交易之後，西蒙在CRISPR Therapeutics中持有的股份爲769,196股。間接受益所有權的性質詳見與交易記錄相關的附註。
有用
沒用